First oral therapy for pulmonary arterial hypertension approved by FDA

 The FDA has approved the endothelin antagonist bosentan (Tracleer® – Actelion) for the treatment of pulmonary arterial hypertension (PAH).

This is the first oral therapy to be cleared for use in this indication and it is expected to be available to patients in the US from early December 2001.